CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

02 4 2024 07:01:11 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

13 3 2024 08:45:14 提供 NetDania Notify

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

12 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

08 3 2024 09:25:24 提供 NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

07 3 2024 09:12:48 提供 NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

06 3 2024 08:45:06 提供 NetDania Notify

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

06 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

05 3 2024 09:02:57 提供 NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

04 3 2024 10:25:20 提供 NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

01 3 2024 08:48:44 提供 NetDania Notify

NetDania - New 12 months High: CORBUS PHARMACEUTICALS HOLDINGS INC. - COMMON STO

29 2 2024 13:30:15 提供 NetDania Notify

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

28 2 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 2 2024 08:50:36 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

02 2 2024 15:01:11 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Pricing of Public Offering

31 1 2024 08:19:41 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Proposed Public Offering

30 1 2024 17:55:29 提供 Nasdaq GlobeNewswire

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

26 1 2024 06:30:00 提供 Nasdaq GlobeNewswire

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

23 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

09 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

18 12 2023 07:00:00 提供 Nasdaq GlobeNewswire